基因编辑公司Intellia Therapeutics Inc（NTLA）今日盘前股价大跌9.25%，引发了市场关注。
消息面上，此次股价下跌主要与公司宣布的一项融资活动有关。Intellia Therapeutics公布了1.8亿美元的后续发行定价，计划发行约1,670万股，发行价为每股10.75美元，这一价格较其前一交易日的收盘价有显著折让，幅度达到18.6%。此类股权融资通常会增加市场流通股数量，并对现有股价产生稀释压力，从而导致股价在短期内承压下跌。
根据公司披露的信息，此次融资旨在为其核心基因编辑疗法的临床开发、未来的商业化上市准备、其他研发项目以及潜在的收购机会提供资金支持。高盛、花旗集团和杰富瑞担任此次发行的联合簿记管理人。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.